drugset / Trial / NCT03148756

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756

Phase 2 Terminated 2 enrolled AbbVie
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will compare dalbavancin to standard of care (SOC) antibiotic therapy for the completion of therapy in patients with complicated bacteremia or infective endocarditis.

Timeline

Start
2017-05-12
Primary completion
2017-08-04
Completion
2017-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalbavancin Other / unclassified 1500 mg Intravenous